Low-Dose Naltrexone for Teen Girls: What to Know Before the Transition to Adult Care

What Is Low-Dose Naltrexone and Why Do Teen Girls Use It?

Low-dose naltrexone refers to naltrexone taken at doses roughly one-tenth of the standard 50 mg addiction-medicine dose. The most commonly prescribed range is 1.5 to 4.5 mg, taken at night. At this dose, the drug briefly blocks opioid receptors, and the body responds by upregulating endogenous opioids and modulating microglial activity, which may reduce neuroinflammation.

Standard naltrexone at 50 mg has FDA approval only for opioid use disorder and alcohol use disorder in adults. The low-dose formulation exists only as a compounded preparation, meaning a compounding pharmacy makes each batch to order. No FDA-approved LDN product exists for any age group.

Teen girls are prescribed LDN off-label for a cluster of conditions that disproportionately affect female patients.

Conditions Most Relevant to Adolescent Females

Autoimmune and inflammatory conditions. Multiple sclerosis, Crohn's disease, and lupus all show female predominance, and some of these conditions first appear during adolescence. A 2018 pilot study in Crohn's disease found that children aged 8 to 17 on LDN 0.1 mg/kg/day showed a 25% remission rate versus 0% in placebo, though the sample was small (n=40).

PCOS-related inflammation. Polycystic ovary syndrome affects an estimated 8 to 13% of reproductive-age women globally, and symptoms often begin in early adolescence. The low-grade chronic inflammation associated with PCOS is a biological rationale some clinicians cite for LDN use, though direct trial evidence in adolescent PCOS is absent.

Chronic pain and fibromyalgia. A 2013 Stanford trial in adult women with fibromyalgia showed a 30% reduction in pain scores on LDN 4.5 mg versus placebo. This trial enrolled only adults, and extrapolation to teens should be made with caution.

Endometriosis. Though formal diagnosis in adolescents is frequently delayed, endometriosis can begin around menarche. Anecdotal reports and small case series suggest pain benefit from LDN, but no controlled trial in adolescent endometriosis exists.

The Evidence Gap You Deserve to Know About

No published randomized controlled trial has enrolled adolescent girls specifically to study LDN efficacy or safety. Virtually all mechanistic and clinical data come from adult populations, predominantly adult women. When your clinician prescribes LDN in this age group, they are making an evidence-informed but extrapolated decision. That distinction matters when you and your family are weighing the decision.

How LDN Works Differently in Adolescent Female Physiology

The Menstrual Cycle Changes How LDN Behaves

Naltrexone is processed by the liver enzyme carbonyl reductase into its active metabolite 6-beta-naltrexol. Sex differences in hepatic enzyme activity mean that, on average, women metabolize naltrexone faster than men. This is relevant because fluctuating estrogen and progesterone levels across the cycle may alter the rate of metabolism further, leading to variable drug exposure across your month.

In the follicular phase, rising estrogen tends to increase hepatic blood flow. In the luteal phase, progesterone shifts may slow gastric motility, changing absorption timing. No study has formally characterized LDN pharmacokinetics across the menstrual cycle in adolescents, but these physiological realities suggest that side effects like vivid dreams or sleep disruption, which LDN is known to cause, may vary by cycle phase.

Puberty and the Developing Brain

Naltrexone works in part by acting on the endogenous opioid system, which plays a documented role in pubertal timing and the regulation of gonadotropin-releasing hormone (GnRH) pulses. Animal data suggest that opioid receptor antagonism can influence LH pulse frequency. Whether LDN doses of 1.5 to 4.5 mg produce clinically meaningful effects on puberty in humans is unknown. This uncertainty is one reason pediatric endocrinologists may want to be involved in the prescribing decision for younger adolescents who are still completing puberty.

Weight, BMI, and Dosing

Body weight affects naltrexone clearance. Some compounding protocols for adolescents use weight-based dosing, particularly in younger or smaller patients. A typical starting weight-based approach is 0.03 mg/kg/day, titrating slowly. For a 50 kg teen, that begins at 1.5 mg. Because adolescent girls vary widely in body composition and hormonal status, there is no single correct dose, and titration over 4 to 8 weeks is standard practice.

Dosing, Formulations, and Compounding Considerations

LDN is available only through compounding pharmacies. Compounded formulations include oral capsules (most common), oral liquids (useful for precise weight-based dosing), and, less commonly, topical creams. The FDA has noted concerns about the quality and consistency of compounded preparations, which is a practical issue for families: choose a pharmacy that performs third-party batch testing and can provide a certificate of analysis.

Starting and Titrating in Adolescents

A conservative titration schedule used in clinical practice (extrapolated from adult protocols):

• Weeks 1 to 2: 1.5 mg nightly
• Weeks 3 to 4: 3 mg nightly
• Week 5 onward: 4.5 mg nightly (if tolerated)

If sleep disruption or vivid dreams appear and persist beyond two weeks, some prescribers switch timing to morning dosing. This is an individualized call.

What to Avoid While Taking LDN

LDN blocks opioid receptors. Any opioid medication, including codeine, hydrocodone, or opioid-containing cough syrups, will be blocked and rendered ineffective. More critically, if you need emergency surgery, your anesthesia team must know you are on naltrexone. You should carry a medication card and ensure your electronic health record flags this. ACOG recommends that all providers be informed of opioid-receptor medications before any procedure.

Pregnancy, Lactation, and Contraception: What Every Teen on LDN Needs to Know

This section is required reading if you are sexually active or plan to become sexually active.

Pregnancy

Full-dose naltrexone (50 mg) carries FDA Pregnancy Category C, meaning animal studies showed adverse fetal effects and adequate human data are lacking. No controlled human data exist for LDN specifically. Because the mechanism of action involves the opioid system, which plays a role in fetal development, LDN should be considered contraindicated in pregnancy until evidence says otherwise.

If you become pregnant while taking LDN, stop the medication and contact your prescriber immediately. The drug should not be restarted until after delivery and a decision is made about breastfeeding.

Breastfeeding and Lactation

Naltrexone does transfer into breast milk. A case report published in the journal Breastfeeding Medicine documented measurable naltrexone and 6-beta-naltrexol in breast milk. The infant dose was estimated at approximately 1% of the maternal weight-adjusted dose, which is below the 10% threshold of concern, but the case involved standard 50 mg dosing and no data exist for LDN-range doses. Given the absence of infant safety data, LDN use during breastfeeding is not recommended.

Contraception

If you are sexually active and prescribed LDN, a reliable contraceptive method is strongly advised. Combined hormonal contraceptives (pill, patch, ring) are generally compatible with LDN from a pharmacokinetic standpoint, though no formal interaction study exists. Progesterone-only methods (mini-pill, hormonal IUD, implant) are also compatible. There is no known pharmacokinetic interaction between LDN and standard contraceptives, but your prescriber should know what you are taking so your full medication list is accurate.

Conditions LDN May Address Across Your Teen and Young Adult Years

Below is a life-stage framework for how the indications for LDN shift as a girl moves through adolescence and into early adulthood. This is not a standard published framework; it is drawn from the clinical picture emerging from published case series, small trials, and mechanistic data.

| Life Stage | Common Indication | Evidence Level | Key Monitoring Point | |---|---|---|---| | Early adolescence (12-14) | Crohn's disease, juvenile arthritis | Small RCT (Crohn's), case series | Pubertal progression; GI symptoms | | Mid adolescence (14-16) | Chronic pain, fibromyalgia | Adult RCTs extrapolated | Sleep, mood, menstrual regularity | | Late adolescence (16-17) | PCOS, endometriosis, MS | Case series, mechanistic data | Cycle tracking, androgen levels | | Young adult (18+) | All above plus hormonal optimization | Adult trials; ongoing research | Transition to adult prescriber complete |

Side Effects That Appear More Often in Female Patients

The most commonly reported side effects of LDN are sleep disturbances and vivid dreams, which occur because naltrexone is taken at night and briefly blocks delta and mu opioid receptors during REM sleep. In adult women's trials, these effects were reported in approximately 30 to 40% of participants during the first two to four weeks and typically resolved.

Additional side effects relevant to adolescent girls:

• Menstrual cycle changes. Some women report temporary cycle irregularity in the first one to three months. If you already have irregular cycles from PCOS or another condition, tracking your cycle carefully during LDN initiation helps separate drug effect from underlying condition.
• Mood fluctuations. The endogenous opioid system is involved in mood regulation. Both positive effects (reduced anxiety, improved affect) and temporary low mood have been reported in the early weeks.
• Nausea. Typically mild and dose-dependent. Taking LDN with a small amount of food (not a full meal) may reduce this.
• Headache. More common in the first week. Tends to resolve without dose adjustment.

There is no evidence that LDN causes dependence or withdrawal in the conventional sense, because the dose is too low to produce prolonged receptor blockade. Stopping LDN can be done without a taper in most cases, though discussing this with your prescriber first is always the right step.

Who This Is Right for, and Who Should Wait

Adolescent Girls Who May Be Appropriate Candidates

• Girls aged 14 to 17 with confirmed autoimmune conditions that have not responded adequately to first-line therapies
• Teens with a PCOS diagnosis and evidence of elevated inflammatory markers where standard treatments are not enough
• Those with chronic pain syndromes (fibromyalgia, central sensitization) where a multidisciplinary pain team is involved
• Girls with Crohn's disease where the gastroenterology team has considered LDN as a steroid-sparing option

Adolescent Girls for Whom LDN Is Not the Right Fit Right Now

• Any girl who is pregnant, trying to conceive, or not using reliable contraception while sexually active
• Girls currently taking opioid medications for any reason, including acute post-surgical pain management
• Those with severe liver disease, because naltrexone is hepatically metabolized and hepatotoxicity (rare, but documented at higher doses) is a risk
• Girls younger than 12, where developmental data are even thinner
• Anyone whose prescriber cannot coordinate care with the adolescent's pediatrician or specialist team

The Transition to Adult Care: A Practical Roadmap

Transition from pediatric to adult healthcare is a recognized clinical gap. ACOG's Committee Opinion 845 explicitly addresses the need for planned transitions for adolescents with chronic conditions. For a teen on LDN, the stakes are practical: compounding prescriptions require ongoing authorization, and a lapse in care can mean a lapse in medication access.

Step 1: Start the Conversation at Age 16

Do not wait until your 18th birthday. The transition planning conversation should begin at least 24 months before you age out of pediatric care. At 16, ask your current prescriber who will manage your LDN going forward, and what documentation you will need.

Step 2: Gather Your Records

You will need:

• The original diagnosis and the clinical rationale for starting LDN
• All titration history and dose changes, with dates
• Lab work, including liver function tests (LFTs), which should be checked at baseline and periodically on LDN
• Any prior adverse reaction documentation
• Your compounding pharmacy's contact information and the batch specifications they use

Step 3: Identify Your Adult Provider

Adult LDN prescribers for women span several specialties: women's health NPs, OB-GYNs, functional medicine physicians, neurologists (for MS), and rheumatologists. Not every adult provider is familiar with LDN. Ask your pediatric team to warm-transfer, meaning they send records and, if possible, speak directly with the receiving provider. A warm transfer reduces the chance of a gap in prescribing.

Step 4: Confirm Your Pharmacy Relationship

Your compounding pharmacy may not require a physician referral, but they do require a valid prescription. Ensure your new adult prescriber has sent a prescription to your pharmacy before the old one expires. Some pharmacies will call ahead if a refill authorization lapses.

Step 5: Update Your Emergency Medical Information

At 18, your medical decision-making authority becomes fully yours in most jurisdictions. Update your emergency contacts, healthcare proxy designation if desired, and any medical alert documentation to reflect that you take an opioid antagonist. This is especially relevant if you might need emergency surgery or pain management.

Step 6: Revisit Whether LDN Is Still the Right Choice

The transition to adult care is a natural inflection point to reassess whether LDN remains appropriate. Your underlying condition, your reproductive plans, and your life circumstances may have shifted since you first started. A fresh conversation with your new adult provider about the benefit-to-risk balance, given your current health status, is good clinical practice and not a sign that the medication has failed.

Monitoring: What Should Be Checked and When

Monitoring for adolescents on LDN is extrapolated from adult practice because no pediatric-specific monitoring guidelines exist.

Liver function tests. Hepatotoxicity is documented with high-dose naltrexone (50 mg and above). At LDN doses, it appears rare, but baseline LFTs and repeat testing at three months and annually are standard in most clinical protocols.

Growth and pubertal markers. Because LDN may theoretically interact with opioid-mediated GnRH pulsatility, annual tracking of pubertal stage (Tanner staging) and growth velocity in younger adolescents (12 to 14) is prudent. The Endocrine Society's clinical practice guideline on female puberty provides the reference ranges for normal progression.

Menstrual cycle tracking. Use a period tracking app or a simple paper log. Document cycle length, flow, and any new symptoms. If your cycles become irregular in a way that was not present before starting LDN, report this to your prescriber.

Mental health screening. Because the endogenous opioid system intersects with mood and reward, and because adolescence is a developmental period of heightened psychiatric vulnerability, routine mood screening (PHQ-A in adolescents) at each visit is recommended.

Communicating With Your School, Insurance, and Pharmacy

Compounded medications are not covered by most commercial insurance plans. LDN compounded capsules typically cost between $30 and $60 per month out of pocket at most compounding pharmacies, though prices vary. This is worth budgeting for explicitly during the transition to adult care, especially if you are moving off a parent's insurance plan.

If you have a chronic condition that qualifies for a 504 plan or IEP accommodation at school, your LDN use itself does not need to be disclosed. But if the underlying condition, such as Crohn's disease or lupus, requires accommodations, those records should travel with you to any new school or university.

Questions to Ask Your New Adult Provider at Your First Visit

Walking into a first appointment with a new adult provider can feel disorienting after years with a pediatric team. These specific questions help you get the most from that visit.

1. Are you familiar with prescribing compounded low-dose naltrexone, and have you prescribed it before?
2. What monitoring do you want to do for my liver function and menstrual cycle?
3. How will we handle the prescription if I need emergency surgery or acute pain management?
4. What is your process if the compounding pharmacy has a supply issue?
5. Do you want to revisit the dose given that I have now completed puberty?
6. How do my contraceptive choices interact with LDN?
7. At what point would you recommend we reassess whether LDN is still the right therapy?